Decera Clinical Education Oncology Podcast

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides a nursing-focused overview on available BTK inhibitors in the treatment of CLL and lymphomas. Topics in this podcast include: Rationale for inhibiting BTK MOA of BTK inhibitors Approved BTK inhibitors Recent clinical trial findings Link to full program, including downloadable slidesets: https://bit.ly/3iwN9Ub Presenter:  Beth...

In this podcast episode, Amy Goodrich, CRNP, discusses nursing perspectives on managing adverse events associated with BTK inhibitor therapy. Topics in this podcast include: BTK inhibitor selectivity BTK inhibitor adverse event profiles Ibrutinib intolerance Management of common adverse events Presenter: Amy Goodrich, RN, MSN, CRNP-AC Research Associate/Nurse Practitioner Sidney Kimmel Comprehensi...

In this episode, Chris Parker, MD, and Bertrand Tombal, MD, PhD, discuss the clinical implications of the latest data on radiopharmaceuticals in the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). Topics include: Data from the PEACE-3 trial on the effect of bone-protective agents on fracture risk with enzalutamide plus radium-223 Efficacy and toxicity of PSMA lut...

In this episode, Caron A. Jacobson, MD; Jae H. Park, MD; and Noopur Raje, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in CAR T-cell therapy, with questions including: At what time in the treatment journey should CAR T-cell therapy be considered? How to select among 3 approved products for relapsed/refractory large B-cell lymphoma?...

In this podcast episode, Donna Catamero, ANP-BC, OCN, CCRC, highlights practical considerations for integrating anti-BCMA–targeted therapy into clinical practice for patients with multiple myeloma after multiple relapses. Don’t forget to listen to part 1 of this series with a discussion on other novel treatment options by Tiffany Richards, PhD, ANP-BC, AOCNP, Nurse Practitioner at the University o...

In this podcast episode, Tiffany Richards, PhD, ANP-BC, AOCNP, highlights practical considerations for integrating novel treatments— selinexor, venetoclax, and melphalan flufenamide—into clinical practice for patients with multiple myeloma after multiple relapses. Check back to hear part 2 of this series with a discussion on BCMA-targeted therapy by Donna Catamero, ANP-BC, OCN, CCRC, Associate Dir...

In this podcast episode,Charise Gleason, MSN, NP-BC, AOCNP, discusses clinical considerations for patients with multiple myeloma after relapse on initial therapy. Topics in this podcast include: Strategies for monitoring for disease progression Disease, therapy, and patient considerations for treatment selection at first relapse Nursing implications and supportive care considerations for patients...

In this podcast episode, Beth Faiman, PhD, MSN, APRN-BC, AOCN, discusses clinical considerations for diagnosis and optimal treatment selection for initial management of patients with multiple myeloma. Topics in this podcast include: IMWG criteria for diagnosing smoldering and active myeloma Risk stratification of smoldering myeloma with 2/20/20 criteria and active myeloma with R-ISS staging Indivi...

In this episode, Linda R. Duska, MD, MPH; Robert L. Coleman, MD, FACOG, FACS; and Leslie Randall, MD, MAS, answer questions from an audience of healthcare professionals on topics related to the management of patients with endometrial and ovarian cancer including:   Adding bevacizumab to chemotherapy in frontline endometrial cancer Lenvatinib and pembrolizumab in MSI-H/dMMR endometrial cancer PARP...

In this episode, Scott R. Plotkin, MD, PhD, and Brian D. Weiss, MD, answer questions from a healthcare professional audience on topics related to NF1 and plexiform neurofibromas including:   Whole exome sequencing for diagnosis When to treat asymptomatic tumors Genetic testing of family members Choosing a MEK inhibitor Supportive care for acneiform rash Other RAS pathway inhibitors Presenters: Sco...

In this episode,  Wassim Abida, MD, PhD; Joaquin Mateo, MD, PhD; and Charles J. Ryan, MD, answer questions from an audience of healthcare professionals on topics related to prostate cancer and PARP inhibition including:   Germline and somatic mutation testing PARP inhibition in earlier stage disease PARP inhibitors plus AR-targeted therapy after progression on AR-targeted therapy PARP inhibition i...

In this episode, David Kaplan, MD, MSc, and Thomas Karasic, MD, review approved immunotherapy options for advanced HCC and answer key questions surrounding use of immune checkpoint inhibitors, with topics including: Current systemic therapy standards of care for patients with advanced HCC Use of single-agent immune checkpoint inhibitor therapy in the first-line setting Assessing bleeding risk Usin...

In this episode, David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, provide expert perspectives on new data from ASCO 2021 presented for endometrial, ovarian, and cervical cancers regarding: Results from a pilot study of pembrolizumab monotherapy in patients with Lynch-like vs sporadic MLH1-methylated endometrial cancer Updated analyses from the phase I GARNET trial, including...

In this podcast episode, Suzanne Lentzsch, MD, PhD, and  Saad Z. Usmani, MD, MBA, FACP, discuss how they select optimal treatment for relapsed/refractory (R/R) multiple myeloma (MM) and answer audience questions from a live webinar. Topics include: Selecting optimal triplet regimen after first relapse Sequencing treatment options after multiple relapses Managing patient expectations when selecting...

In this episode, Nathan Pennell, MD, PhD; Jamie E. Chaft, MD; and Stephen V. Liu, MD, answer questions asked by an audience of healthcare professionals during a live CCO webinar on biomarker-driven therapies for NSCLC. Topics include: Choosing between immune checkpoint inhibitor monotherapy and combination therapy with an immune checkpoint inhibitor plus chemotherapy for newly diagnosed NSCLC Inco...

In this episode,Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and  Helena A. Yu, MD, answer audience questions from a live webinar regarding clinical data on antibody–drug conjugates in NSCLC including: Biopsies and biomarker testing considerations Tumor heterogeneity and targeting of brain metastases Liquid biopsies Sequencing of ADCs following previous therapy Toxicity management Presenters...

In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations key considerations for hepatologists, oncologists, and other healthcare professionals in the contemporary use of immune checkpoint inhibitors for treating specific case patients with advanced hepatocellular carcinoma, including: First-line systemic treatment for a patient with Child-Pugh A liver function and...

In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany. Topics include: Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapy Results from IMvigor130 and KEYNOTE-361 trials on concurrent immune...

In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss toxicities associated with FGFR inhibitors used in the treatment of urothelial cancer and other malignancies     Presenters: Ignacio Durán, MD, PhD Associate Professor GU Oncology Program Leader Department of Medical Oncology Hospital Universitario Marques de Valdecilla-Idival Santander, Spain Alison Birtle, MD, FR...

In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including: Key data supporting the clinical use of these agents Optimal sequencing and timing of use Dosing considerations Key adverse events Presenters: Joleen Hubbard, MD Associate Professor Gastrointestinal Oncologist Medical...

In this episode,  Shaji K. Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD, and Jesús F. San-Miguel, MD, PhD, answer audience questions from a recent Clinical Care Options live webinar on managing multiple myeloma. Topics include: Approaches for managing smoldering multiple myeloma Insights on new strategies for managing newly diagnosed multiple myeloma Incorporating...

In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostate cancer including: PARP inhibitors combined with androgen receptors Phase III trials of PARP inhibitors with androgen receptor–directed therapy PARP inhibitors combined with...

In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the underlying rationale for using PARP inhibitors in combination with other therapies to treat men with prostate cancer including: Possible synergy between PARP inhibitors and androgen receptor–directed therapy Rationale for PARP inhibitors and immunotherapy combinations Benefits and challenges of combining DNA damaging a...

In this episode, Jubilee Brown, MD, and Ursula Matulonis, MD, provide expert perspectives on new data from SGO 2021 presented for endometrial and ovarian cancer including: Results from KEYNOTE-775, a phase III trial of lenvatinib plus pembrolizumab in advanced endometrial cancer Results from the confirmatory phase III ARIEL4 evaluating rucaparib vs chemotherapy in BRCA -mutated relapsed ovarian ca...

In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including: Germline and somatic mutation testing Managing adverse events with PARP inhibitors Resistance to PARP inhibitors Implications of monoallelic vs biallelic BRCA mutations ATM mutations and PARP inhibitor sensit...